Strengths and Limitations:•We performed a rigorous systematic review and meta-analysis of randomized controlled trials evaluating catheter ablation (CA) of any energy modality compared with antiarrhythmic drugs (AADs) in patients with atrial fibrillation (AF).•Our study is one of very few to focus on patient-reported outcomes, including health-related quality of life (HRQL), AF-related symptoms, and the need for repeat ablations.•Of the 13 RCTs comparing CA vs AADs and reporting HRQL outcomes, data from only 2 to 5 could be pooled at each time point due to inconsistencies in reported time points and variation in tools of HRQL assessment.•There were not enough trials evaluating cryoballoon ablation (CBA) vs AADs to meta-analyze.

Atrial fibrillation (AF) is a common arrhythmia, affecting an estimated 1%-2% of the population worldwide.[@bib1] The prevalence of AF increases with age, and the combined effects of aging and AF can be debilitating, particularly with respect to health-related quality of life (HRQL). HRQL is defined as "the extent to which one's usual or expected physical, emotional and social well-being are affected by a medical condition or related treatment."[@bib2] Compared with age-matched healthy controls, patients with AF consistently report lower HRQL.[@bib3] Furthermore, women more often report greater symptom burden and poorer HRQL, in comparison with men.[@bib4]

The management of AF involves anticoagulation therapy to reduce the risk of stroke and medications that control rate or rhythm to decrease symptoms and improve HRQL.[@bib5] Despite rate control being very effective in some individuals, many patients remain highly symptomatic.[@bib6] To alleviate patient symptoms and improve HRQL, restoration and maintenance of sinus rhythm can be achieved with antiarrhythmic drugs (AADs).[@bib5] However, these medications may be associated with serious side effects[@bib7] and have only modest efficacy at maintaining sinus rhythm over the long term.[@bib8]

Catheter ablation (CA) is an alternative to pharmacologic therapies that have failed to control AF symptoms, particularly in those with paroxysmal AF (PAF).[@bib9] The main driver for choosing this treatment option is the anticipated improvement in AF-related symptoms and HRQL. Numerous studies have shown the superiority of CA over AADs in reducing AF recurrence, with patients having larger overall improvements in HRQL scores compared with baseline, vs those treated with pharmacologic therapy.[@bib10], [@bib11], [@bib12] Of note, across trials, only 2 trials[@bib13]^,^[@bib14] have compared between treatment differences (ie, HRQL scores in CA patients vs HRQL scores in AAD patients); in the recently published Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial, the mean Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire summary score at 12 months was 5.3 points higher favouring radiofrequency ablation (RFA) over AADs.[@bib13] As there is limited randomized controlled trial (RCT) evidence evaluating HRQL between CA and AADs, an updated synthesis of this literature is needed to inform quality treatment decisions.

Methods {#sec1}
=======

The study protocol and methods have been published previously.[@bib15] Briefly, this systematic review and meta-analysis was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and reported following the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) statement for meta-analysis in health care interventions[@bib16] (PRISMA Checklist, [Supplemental Table S1](#appsec1){ref-type="sec"}).

Eligibility criteria {#sec1.1}
--------------------

We included RCTs that evaluated CA of any energy modality (eg, cryoballoon ablation \[CBA\] or RFA) compared with AADs, irrespective of blinding, publication status, or language, in patients with persistent AF or PAF. Observational studies, RCTs that performed CA on other patient populations, atrial flutter, and ventricular tachycardia were excluded. Surgical AF ablation studies were beyond the scope of this review.

Search strategy and study selection {#sec1.2}
-----------------------------------

A comprehensive search strategy was conducted from database inception to March 17, 2020, to identify published, in-press, and unpublished studies. Databases included Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Medical Literature Analysis and Retrieval System Online (MEDLINE), Cumulative Index of Nursing and Allied Health Literature (CINAHL), and Excerpta Medica database (EMBASE). The search strategy used a combination of keyword and database-specific subject headings for the following concepts: "atrial fibrillation," "catheter ablation," and "randomized controlled trial" (see [Supplemental Appendix](#appsec1){ref-type="sec"} for example search strategy). We examined citations of included studies to identify additional studies not identified in the electronic search. Ongoing trials were identified using the World Health Organization International Clinical Trials Registry Platform and [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0010}. We contacted experts to inquire about additional studies and unpublished data.

Three reviewers (K.S.A., T.A., and S.H.) independently examined the titles, abstracts, and full-text articles retrieved by the search. Studies were included for full-text review on the basis of agreement between 2 reviewers or when there was disagreement or uncertainty. Data from multiple reports of the same study were linked together and used to supplement information obtained from the primary report.

Data extraction {#sec1.3}
---------------

After calibration exercises, 3 reviewers (K.S.A., T.A., and S.H.) used standardized forms to independently perform data extraction, in duplicate, with discrepancies resolved through consensus. In instances of missing or unclear information, study authors were contacted for clarification.

Data were abstracted from individual studies on the following variables: study location, duration of the trial, follow-up duration, blanking periods, study design, number of trial sites, inclusion/exclusion criteria, number of participants randomized, number of participants analysed, attrition, age, sex, type of AF, prior AAD therapy, type of CA, HRQL, AF-related symptoms, and number of repeat CA procedures.

Agreement between the 3 reviewers on study eligibility and risk of bias assessment was performed using the kappa statistic for inter-rater reliability.

End points and subgroup analyses {#sec1.4}
--------------------------------

The primary analyses evaluated whether CA or AADs improved patient HRQL measured by generic and/or disease-specific instruments in the acute phase (3-6 months after treatment) and long term (12-60 months after treatment). Secondary outcomes included the frequency and severity of AF-related symptoms in the acute phase and long term, as well as the number of repeat procedures needed to maintain sinus rhythm.

Planned subgroup analyses included (1) the effect of CA vs AADs in treatment naïve patients vs after failed AADs; (2) the effect of crossovers on HRQL (ie, patients randomized to AADs receiving CA later in the trial); (3) the effect of different CA modality (eg, cryoballoon or radiofrequency); and (4) differences in effects based on questionnaire type. Sensitivity analyses were planned to evaluate potential sources of bias resulting from variability in studies.

Risk of bias and quality assessment {#sec1.5}
-----------------------------------

Risk of bias was assessed as "low risk," "some risk of bias," and "high risk of bias," using the Cochrane Collaboration Risk of Bias 2.0 tool,[@bib17] for the following measures: adequacy of sequence generation, adequacy of allocation concealment, adequacy of blinding for participants, study personnel and outcome assessors, completeness of outcome data for each primary and secondary outcome, selective outcome reporting, and other potential sources of bias (ie, funding). Early stopping for benefit and observation of intention-to-treat principle were also assessed. Risk of bias tables were completed independently by the 3 reviewers (K.S.A., S.H., and T.A.) in pairs and compared for consensus.

GRADEpro GDT software (GRADEpro GDT: GRADEpro Guideline Development Tool \[Software\]. McMaster University, 2015 \[developed by Evidence Prime, Inc.\]. Available from [gradepro.org](http://gradepro.org){#interref0010}) was used to generate Summary of Findings and Evidence Profile tables (K.S.A., M.H.M.). Confidence in effect estimates of the outcome measures were rated according to the quality of evidence using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach for systematic reviews.[@bib18] According to this approach, RCTs are ranked as high quality and downgraded for risk of bias, inconsistency, indirectness, imprecision, and publication bias. We planned on evaluating publication bias using funnel plots.

Statistical analysis {#sec1.6}
--------------------

We used inverse-variance random-effects models to compare treatment effects, incorporating for heterogeneity between studies. Data were pooled at consistent time points across studies, 3, 6, 12, 24, 48, and 60 months after treatment to measure differences between interventions.

Weighted mean differences were calculated for continuous outcomes measured on the same scale between studies and standardized mean differences (SMD) were calculated for continuous outcomes measured on different scales between studies. When the data were unavailable numerically, we used approximations based on graphic output. For studies reporting only means and interquartile ranges, means and standard deviations were estimated.[@bib19] Point estimates with 95% confidence intervals are reported.

Studies were evaluated for clinical heterogeneity using the χ^2^ test for homogeneity with an alpha = 0.10 and the *I*^2^ statistic to quantify inconsistency.[@bib20] We considered *I*^2^ values of 0%-40% as not important, 30%-60% as moderate heterogeneity, and 75%-100% as considerable heterogeneity.[@bib20] Review Manager (RevMan) Version 5.3.5 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014) software was used to enter and analyse the study data.

Results {#sec2}
=======

Literature search and study selection {#sec2.1}
-------------------------------------

We identified 15,878 records. After removing duplicates, 11,023 records were screened by title and abstract (Ƙ = 0.74), 262 full-text articles were assessed for eligibility (Ƙ = 0.87), and 13 studies[@bib10]^,^[@bib11]^,^[@bib13]^,^[@bib14]^,^[@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29] comprising 20 articles were included ([Fig. 1](#fig1){ref-type="fig"}).Figure 1Flow diagram of study selection.

Study characteristics {#sec2.2}
---------------------

A total of 4093 patients were included in the 13 studies, ranging from 30 to 2204 patients. Most studies were from Europe and North America, and all were published between 2003 and 2019. [Table 1](#tbl1){ref-type="table"} summarizes the study characteristics of the included studies.Table 1Study characteristics+/Author, yearCountry of recruitmentMulti or single centreTotal patients (n = 4093)Number comparator patientsNumber RFA patientsComparatorsRandomizationPrior treatment with AADHRQL instrumentAF-related symptoms instrumentHRQLSymptomsDuration of follow-upPercentage with AF recurrence at end of FU comparatorPercentage with AF recurrence at end of FU RFANumber of repeat ablationsMark, 2019[@bib13]USA, Australia, Canada, China, Czech Republic, Germany, Italy, Korea, Russia, UKMulti220410961108CBA or RFA vs AADs1:1NoAFEQT\
SF-36Mayo AF-Specific Symptom Inventory\
AFSS√√5 y69.549.9215 (19.4)Morillo, 2014[@bib25]Canada, Germany, Czech Republic, USA, ItalyMulti1276166RFA vs AADs1 to 1NoEQ-5DNo√N/A2 y72.154.510 (15.1)Sohara, 2016[@bib29]JapanMulti14343100RFA vs AADs2 to 1 (CA to AAD)YesSF-36No√N/A9 mo95.341.0Not reportedPappone, 2011[@bib28]ItalySingle1989999RFA vs AADs1 to 1YesSF-36No√N/A4 y87.927.327 (27.3)Mont, 2014[@bib24]SpainSingle1464898RFA vs AADs2 to 1 (CA to AAD)YesAF-QOLNo√N/A1 y56.429.68 (8.2%)Jais, 2008[@bib10]USA, France, SwitzerlandMulti1125953RFA vs AADs1 to 1YesSF-36AF Symptom Frequency and Severity Checklist√√1 y771123 (43.4)Packer, 2013[@bib27]USA, CanadaMulti24582163CBA vs AADs2 to 1 (CA to AAD)YesNoNoN/AN/A1 y92.730.131 (19.0%)Hummel, 2014[@bib22]USA, the NetherlandsMulti21072138RFA vs AADs2 to 1 (CA to AAD)YesAF Symptom and QOL SurveysAF Symptom and QOL Surveys√√6 mo73.644.248 (34.8%)Reynolds, 2010[@bib14]USA, Canada, Brazil, Italy, Czech RepublicMulti15956103RFA vs AADs2 to 1 (CA to AAD)YesSF-36AF Symptom Frequency and Severity Checklist√√9 mo843413 (12.6)Wazni, 2005[@bib11]Italy, Germany, USAMulti703733RFA vs AADs1 to 1NoSF-36No√N/A1 y63134 (12.1%)Nielsen, 2012[@bib26]DenmarkMulti294146148RFA vs AADs1 to 1NoSF-36, EQ-5DArrhythmia Specific questionnaire in Tachycardia and Arrhythmia√√5 y291458 (39.2%)Krittayaphong, 2003[@bib23]ThailandSingle301515RFA vs AADs1 to 1YesSF-36No√√1 y6021.4Not reportedBlomstrom-Lundqvist, 2019[@bib21]Sweden, FinlandMulti1557679RFA or CBA vs AADs1:1YesSF-36European Heart Rhythm Association Score√√1 y18.72314 (18.7%)[^1]

Patient characteristics {#sec2.3}
-----------------------

Patients were predominantly male (73.8%), with a weighted mean age of 56.3 ± 8.8, and had mostly PAF (42.9%-100%). Over two-thirds had failed ≥1 AADs. Rates of cardiac risk factors ranged from 2.0% to 80.6%, whereas LA size and LVEF were consistent across studies ([Table 2](#tbl2){ref-type="table"}).Table 2Patient characteristicsAuthorMale (%)Mean age of RFA patientsMean age of comparator patientsWeighted agePAF (%)Persistent AF (%)Failed AADs (%)Naïve (%)HTN (%)DM (%)CAD/MI (%)LA size (cm) RFALA size (cm) comparatorMean weighted LA size (cm) (SD)Mean LVEF (SD) RFAMean LVEF (SD) comparatorMean weighted LVEF (SD)Mark[@bib13]6367.5 ± 2.967 ± 2.967.3 ± 2.942.947.338.661.480.625.519.2NRNRNRNRNRNRMorillo[@bib25]75.656.3 ± 954.3 ± 11.755.3 ± 10.497.62.442.557.541.73.96.34.0 (0.5)4.3 (0.5)4.2 (0.5)61.4 (4.8)60.8 (7.0)61.1 (5.9)Sohara[@bib29]80.458.8 ± 10.461 ± 1059.3 ± 10.3100.00.075.524.552.44.93.53.8 (0.6)3.8 (0.5)3.8 (0.53)66.7 (6.1)66.5 (6.5)66.6 (6.4)Pappone[@bib28]67.255 ± 1057 ± 1056 ± 10100.00.0100.00.056.14.52.04.0 (0.6)4.0 (0.6)4.0 (0.6)60 (8)61 (6)60.5 (7)Mont[@bib24]77.455 ± 955 ± 955 ± 90.0100.0100.00.044.5NRNR4.1 (0.5)4.3 (0.5)4.2 (0.5)61.1 (8.8)60.8 (9.7)60.9 (9.4)Jais[@bib10]83.949.7 ± 10.752.4 ± 11.450 ± 11100.00.0100.00.025.92.7NR3.9 (0.6)4.0 (0.6)3.9 (0.6)63.1 (11)65.6 (7.2)64.3 (9.2)Packer[@bib27]77.157 ± 956 ± 956.3 ± 9100.00.0100.00.042.47.38.64.0 (0.5)4.1 (0.6)4.1 (0.57)61 (6)60 (6)60.3 (6)Hummel[@bib22]83.359.6 ± 8.360.7 ± 8.960.3 ± 8.70.0100.065.734.359.014.319.04.5 (0.5)4.6 (0.5)4.6 (0.5)54.7 (7.1)54.9 (6.7)54.8 (6.8)Reynolds[@bib14]66.555.8 ± 1.856.1 ± 3.255.9 ± 2.3100.00.0100.00.048.510.2NR4.0 (0.1)4.0 (0.1)4.0 (0.1)62.3 (2)62.7 (2)62.6 (2)Wazni[@bib11]NA53 ± 854 ± 854 ± 895.74.30.0100.0NRNRNRNRNRNR53 (50)54 (6)53.5 (5.5)Nielsen[@bib26]70.156 ± 954 ± 1055 ± 10100.00.00.0100.032.75.42.74.0 (0.6)4.0 (0.5)4.0 (0.55)NRNRNRKrittayaphong[@bib23]63.355.3 ± 10.548.6 ± 15.451.9 ± 1370.030.060.040.036.713.36.74.0 (0.7)3.9 (0.7)3.9 (0.7)63.7 (9.5)61.8 (8.8)62.7 (9.2)Blomstrom-Lundqvist[@bib21]77.455.8 ± 10.656.3 ± 8.956.0 ± 9.872.927.1100.00.038.73.93.24.2 (0.6)4.2 (0.5)4.2 (0.55)56.2 (7.2)56.1 (7.7)56.1 (7.4)[^2]

Risk of bias {#sec2.4}
------------

Most trials had low risk of bias for 5 of 7 categories ([Supplemental Fig. S1](#appsec1){ref-type="sec"}); however, almost all trials were at high risk of bias because of lack of blinding of both participants and personnel for outcome assessment.

Quality of evidence {#sec2.5}
-------------------

Because of concerns with risk of bias and imprecision, evidence for HRQL and symptoms were downgraded from high to "low." The GRADE summary of quality evaluation for the HRQL outcomes and AF-related symptoms is presented in [Supplemental Table S2](#appsec1){ref-type="sec"}.

Publication bias was not evaluated using a funnel plot, as \< 10 studies were included for each outcome.[@bib17]

Outcome analyses {#sec2.6}
----------------

For the HRQL analyses, 2 studies assessed it with tools other than the Short Form-36 (SF-36) survey.[@bib22]^,^[@bib24] In the AF-QOL, the physical and psychological components were analysed together with the SF-36 physical and mental component scores, respectively. For the AF symptom and QOL surveys, the physical and mental scores were analysed together with the SF-36 physical and mental component scores, respectively.

Key analyses are shown in [Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}. Individual forest plots for each outcome, by follow-up time point, can be found in [Supplemental Figures S2-S14](#appsec1){ref-type="sec"}.Figure 2Physical and Mental Component Summary scores at 3, 6, 12, and ≥48 months: as measured by the SF-36 (0-100). A positive change from baseline (right axis) to follow-up indicates an improvement in HRQL, whereas a negative change (left axis) indicates a worsening of HRQL. AAD, antiarrhythmic drug; CI, confidence interval; HRQL, health-related quality of life; RFA, radiofrequency ablation; SF-36, Short Form-36; SMD, standardized mean difference.Figure 3AF-symptom frequency at 3, 6, 12, 24, and 60 months: AF-symptom frequency as measured by the AF Symptom Frequency and Severity Checklist and the University of Toronto Atrial Fibrillation Severity Scale. A negative change (left axis) between baseline and follow-up indicates an improvement in symptoms, whereas a positive change (right axis) indicates a worsening of symptoms. AAD, antiarrhythmic drug; AF, atrial fibrillation; CI, confidence interval; RFA, radiofrequency ablation; SMD, standardized mean difference.Figure 4AF-symptom severity at 3, 6, 12, 24, and 60 months: AF-symptom severity as measured by the University of Toronto Atrial Fibrillation Severity Scale and AF Symptom Frequency and Severity Checklist (AFSS). A negative change (**left axis**) between baseline and follow-up indicates an improvement in symptoms, whereas a positive change (**right axis**) indicates a worsening of symptoms. AAD, antiarrhythmic drug; AF, atrial fibrillation; CI, confidence interval; RFA, radiofrequency ablation; SMD, standardized mean difference.

Of the 13 RCTs comparing CA performed with RFA energy vs AADs and reporting HRQL outcomes, data from only 2-5 studies could be pooled at each time point due to inconsistencies in reported time points and variation in tools of HRQL assessment. There were not enough trials evaluating CBA vs AADs that reported patient HRQL to meta-analyse.

One study contributed over half of all patients.[@bib13] We performed a sensitivity analysis by removing this study's data from all applicable outcomes (see [Supplemental Fig. S15](#appsec1){ref-type="sec"}). Most outcomes did not change with the exception of the EuroQol-5 Dimension (EQ-5D) scales at 12 months, Mental Health at 12 months, and AF symptom frequency at 3 months, which all went from slightly favouring RFA to demonstrating no difference between treatments. Interestingly, AF symptom severity at 6 months and General Health at 12 months both showed a stronger association favouring RFA over AADs with the removal of CABANA data.

Two trials[@bib13]^,^[@bib21] combined RFA and CBA in their CA strategy and did not report the data separately. We first pooled both studies to see if their effects were similar (see [Supplemental Fig. S16](#appsec1){ref-type="sec"}) before pooling them with the other study data.

RFA vs AADs {#sec2.7}
-----------

In the RFA vs AAD analyses, RFA in the acute phase (3-6 months) was associated with a significant increase in both the Physical Component Summary (PCS) score (3 months' SMD = 0.58 \[0.39-0.78\]; *P* \< 0.00001, *I*^2^ = 6%, 3 trials, n = 443) (6 months' SMD = 0.45 \[0.23-0.66\]; *P* \< 0.0001, *I*^2^ = 0%; 3 trials, n = 412) and the Mental Component Summary (MCS) score (3 months' SMD = 0.57 \[0.37-0.77\]; *P* \< 0.00001; *I*^2^ = 0%, 3 trials, n = 443) (6 months' SMD = 0.55 \[0.33-0.77\]; *P* = 0.00001, *I*^2^ = 0%, 3 trials, n = 412) at 3 and 6 months ([Fig. 2](#fig2){ref-type="fig"}) in comparison with AADs. At 12 months, both the PCS and MCS scores still showed a significantly greater improvement favouring RFA over AADs ([Supplemental Figs. S2](#appsec1){ref-type="sec"} and [S3](#appsec1){ref-type="sec"}). Only 1 trial reported PCS and MCS summary scores at 24 months preventing meta-analysis at this time point.[@bib30] By 48 months after intervention, no differences in PCS scores were observed between treatment strategies; however, a very small statistically significant difference favouring RFA over AADs was seen in the MCS scores ([Supplemental Figs. S2](#appsec1){ref-type="sec"} and [S3](#appsec1){ref-type="sec"}).

For all 8 SF-36 subscales, some improvements in HRQL were observed in the initial 6-12 months after CA ([Supplemental Figs. S7-S14](#appsec1){ref-type="sec"}); however, the results were not consistent across subscales or time points. Long-term improvements were observed favouring RFA in comparison with AADs in 6 of 8 SF-36 subscales including General Health, Physical Functioning, Bodily Pain, Mental Health, Social Functioning, and Vitality ([Supplemental Figs. S8, S10-S12](#appsec1){ref-type="sec"}, and [S14](#appsec1){ref-type="sec"}).

Because of the small number of trials measuring HRQL at each time point, we were only able to perform the following subgroup analyses: (1) the effect of CA vs AADs on HRQL in treatment naïve patients and (2) the effect on HRQL on AAD patients crossing over to CA. Of the 4 trials comparing CA vs AADs as first-line treatment,[@bib11]^,^[@bib13]^,^[@bib25]^,^[@bib26] we were able to pool HRQL data from 3 of these trials at 12 months after treatment that assess the impact of CA vs AADs on treatment naïve patients with AF.[@bib13]^,^[@bib25]^,^[@bib26] After 12 months, there was no difference in HRQL scores between treatment groups, as measured using the EQ-5D (MD = 0.02 \[−0.00, 0.04\]; *P* = 0.18, 3 trials, n = 2172) ([Supplemental Fig. S4](#appsec1){ref-type="sec"}).

Three trials reported summary HRQL data without crossovers and only at 3 months after randomization.[@bib10]^,^[@bib14]^,^[@bib22] At 3 months, there were significant increases in both the PCS and MCS summary scores favouring CA performed with RFA energy vs AADs ([Supplemental Figs. S2](#appsec1){ref-type="sec"} and [S3](#appsec1){ref-type="sec"}).

For AF-related symptoms, significant decreases in symptom frequency were observed acutely (3-6 months), favouring CA performed with RFA vs AADs ([Fig. 3](#fig3){ref-type="fig"}) and diminished by 12 months. Similar results were seen for AF symptom severity ([Fig. 4](#fig4){ref-type="fig"}).

The number of repeat ablations varied significantly between trials, from 4 (12.1%) to 215 (19.4%) as did the percentage of patients with AF recurrence (11%-54.5% in the RFA arm) ([Table 1](#tbl1){ref-type="table"}). As most studies did not report the exact timing of when these repeat ablations occurred, we were not able to determine their sequencing in relation to AF symptom recurrence. Drug-related side effects and lack of efficacy were the most common reasons why patients with AF discontinued treatment or crossed over to the CA arm where permitted. Side effects ranged from bradycardia, thyrotoxicosis, sexual dysfunction, and gastrointestinal effects to stroke and pulmonary vein stenosis.

Discussion {#sec3}
==========

We performed a meta-analysis evaluating whether CA or AADs improved HRQL, AF-related symptoms, and the number of repeat ablations needed to maintain sinus rhythm. Our analyses demonstrated that CA performed with RFA energy improves both HRQL and AF-related symptoms in the acute phase (3-6 months); however, these results were not consistently observed in long term (12-60 months). The number of repeat ablations needed, as well as the percentage of patients with AF recurrence at the end of follow-up, varied significantly between trials.

Our results corroborate with a previously published meta-analysis from Siontis et al.,[@bib31] who evaluated published and unpublished HRQL data from RCTs of CA performed with RFA energy vs AADs for symptomatic AF. They found that CA demonstrated significant improvements in 3 of 8 SF-36 subscales and the MCS summary score, 3 months after procedure, but these effects diminished by 6 months.[@bib31] We also observed that CA demonstrated significant improvements in the PCS and MCS scores and 8 of 8 SF-36 subscales in the 3 months after procedure compared with AADs, but these effects were only sustained in the long term in 5 of 8 subscales.

Our results differ, likely because they included RCTs comparing CA with or without subsequent AADs after procedure. We focused solely on the effect of CA itself without the addition of AADs after blanking, to evaluate the effect of each treatment method separately. This may explain why we found more HRQL differences favouring CA in the acute phase, whereas Siontis et al. did not. We also included the recently published CABANA trial[@bib13] that contributed substantial weight in meta-analysis of HRQL due to their large patient population, thus driving the overall effects to favour CA. The mixed patient populations of the included trials could be another reason for why CA only showed improvement in HRQL and symptom burden in the acute phase. Most RCTs included patients with AF who had already failed AADs and only 4 of the RCTs studied treatment naïve patients, with 3 of these measuring HRQL at the same time point, 12 months after CA using the EQ-5D.[@bib13]^,^[@bib25]^,^[@bib26] When meta-analysed, no differences were observed between treatment strategies. More trials comparing CA vs AADs in naïve individuals are needed to definitively assess their treatment-related impact on HRQL and AF symptoms.

Results from Siontis et al.'s meta-analysis, and ours, raise an important question as to why the HRQL-related effects of CA do not seem to be maintained in the long term. One explanation relates to the current limitations of generic HRQL surveys, which measure overall "global change" compared with baseline status.[@bib32] Generic HRQL surveys are effective in assessing general levels of HRQL in a variety of patient populations, but they lack specificity to distinguish between different disease states.[@bib33] Another issue is the short timeframe for HRQL measurement, with most asking about HRQL and symptoms in the 4 weeks before their administration. This short recall timeframe, combined with infrequent administration, limits the utility of these instruments to detect more temporally nuanced changes in the clinical status of patients with AF. It may be that a longer-term impact on HRQL, if present, is not being detected by virtue of insensitive measurement bias.

Several AF-specific tools have come into widespread use in the past few years.[@bib34]^,^[@bib35] Their additive value lies with their frequent capture of experiences of patients with AF and they assess domains that are relevant and exclusive to AF, thereby increasing their sensitivity to HRQL changes.[@bib36] Only 3 of 13 RCTs we found measured HRQL using an AF-specific survey and all at differing time points. Future RCTs of CA should use AF-specific HRQL instruments at standardized time points to assess the impact of CA as a treatment option for patients with AF.

The potential "placebo" effect of the more invasive CA over AADs cannot be discounted for the initial improvement of HRQL and AF-related symptoms. As an example, in the ORBITA trial, percutaneous coronary intervention was compared head to head with a sham procedure, and despite percutaneous coronary intervention-improving haemodynamic and imaging indices, it did not improve exercise time or symptoms.[@bib37] An apparent benefit of CA over AADs is not surprising, given the considerable interventional nature of the procedure. An RCT using a placebo design would help tease out the real effects of the procedure itself.

Perhaps the most important question is, despite the increased emphasis on patient-reported outcomes in AF, only a minority of trials collect and report HRQL, with very few using AF-specific instruments.[@bib38] The recently published CAPTAF trial[@bib21] was the first that we have seen to measure HRQL as its primary outcome, with freedom from AF recurrence and AF burden collected as secondary outcomes. More broadly, Steinberg et al.[@bib38] measured how frequently patient-reported outcomes were collected in registered clinical trials of patients with AF over a 19-year period. Of 1709 registered studies, only 14% included patient-reported outcomes, with most describing HRQL outcomes using generic rather than disease specific tools. This echoes our own findings, as we were only able to pool data from 2 to 5 trials for each HRQL outcome data due to inconsistencies in reported time points and variation in tools of HRQL assessment. Most notably, this highlights the lack of attention paid by the scientific community to outcome measurements that are most relevant to patients. Future AF trials should collect and publish HRQL outcomes at consistent time points so that patients and clinicians can decide on the best treatment options.

Limitations {#sec4}
===========

The RCTs included in these analyses had differing follow-up periods, AAD and anticoagulation regimens, and AF definitions. We could only analyse data at the study level and not at the patient-level data.

Patient crossovers may have diluted the differences between treatments. Given that most of the RCTs allowed crossovers to varying degrees at differing time points, it is likely a big contributor to the equalization in HRQL and symptoms reported between groups over time.

Another source of bias is that a third of patients (34.1%; 1398 of 4093) had failed ≥ 1 AADs before treatment. It is possible that AAD failures were not randomized in the same proportion as treatment naïve patients, thus leading to a bias favouring RFA over AADs.

The SF-36 PCS, MCS, and 8 subscale scores were not available across similar time points, limiting the amount of data to pool for analysis. We were not able to evaluate the benefit of CBA vs RFA, as only 2 of 4 trials comparing these had HRQL data and at different time points.

Conclusions {#sec5}
===========

There is low-quality evidence from few RCTs suggesting that CA performed with RFA is more effective in improving short-term physical and mental health than AAD therapy in patients with AF with prior failed AAD treatment. However, these benefits decrease over time such that patients who received AAD therapy show an improvement in both physical and mental health, whereas patients who received CA generally remain consistent in their HRQL scores. Similar results were seen for AF-related symptom frequency and severity. There is a need for more trials reporting HRQL and AF-related symptoms at consistent time points to definitively assess the effectiveness of CA for the treatment of patients with AF.
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[^1]: AAD, antiarrhythmic drug; AF, atrial fibrillation; AFEQT, Atrial Fibrillation Effect on Quality of Life; AFSS, University of Toronto Atrial Fibrillation Severity Scale; CA, catheter ablation; CBA, cryoballoon ablation; EQ-5D, EuroQol-5 Dimensions; FU, follow-up; HRQL, health-related quality of life; RFA, radiofrequency ablation; SF-36, Short Form-36.

[^2]: AAD, antiarrhythmic drug; AF, atrial fibrillation; CAD, coronary artery disease; comparator, antiarrhythmic drugs; DM, diabetes mellitus; HTN, hypertension; LA, left atrial; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NR, not reported; PAF, paroxysmal atrial fibrillation; RFA, radiofrequency ablation; SD, standard deviation.
